Artelo Biosciences (ARTL) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.9 million vs $453,907), about 4.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | SXTC |
|---|---|---|
| Share price | $3.44 | $0.3435 |
| Market cap | $1.88M | $453.91K |
| 1-day change | +2.09% | -87.86% |
| EPS (TTM) | $-136.26 | $-730.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $83,760.00 |
| 52-week low | $3.33 | $0.31 |
| Distance from 52-week high | -98.08% | -100.00% |
| Average volume | 480.92K | 4.71M |
| Shares outstanding | 547.77K | 1.32M |
| Employees | 7 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Artelo Biosciences is about 4.2 times larger than China SXT Pharmaceuticals by market value ($1.88M vs $453.91K).
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
ARTL vs SXTC FAQ
Which is bigger, Artelo Biosciences or China SXT Pharmaceuticals?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.88M compared with $453.91K for China SXT Pharmaceuticals (SXTC).
Are Artelo Biosciences and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.